BNTX Earnings

BNTX reported its earnings on 2026-03-10, showcasing a revenue of 1.06B against an estimate of 881.23M, resulting in a 19.87% surprise. The EPS was -0.38, surpassing the expected -0.22 by -72.73%. The stock experienced a -17.88% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following BNTX's earnings announcement on 2026-03-10, the stock price moved by -17.88% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, BNTX's stock price tends to shift by an average of 4.76% in the 10 days leading up to earnings and 0.8% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate BNTX's annual revenue to reach 219.20M, while the EPS is projected at -2.03. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between BNTX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, BNTX's stock price typically moves by 4.76% in the 10 days before its earnings and 0.8% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -2.03 and revenue of 219.20M.

The earnings call highlights strong financial metrics with increased revenue guidance and reduced expenses, but these are offset by lower revenues from COVID-19 vaccines and expected losses in 2025. The Q&A reveals uncertainties, such as unclear details about the new company and management transitions, which may cause investor caution. Although there's potential for positive developments in oncology, the lack of immediate revenue from these initiatives tempers optimism. Overall, the mixed signals suggest a neutral impact on the stock price in the short term.